Wang et al. confirmed that colorectal cancer patients with PIK3CA mutation showed worse response to first-line chemotherapy than those without PIK3CA mutation, which may be related to the activation of the PI3K-Akt signaling pathway caused by mutations in exon 9 and 20 in PIK3CA33. This evidence concerns the gene PIK3CA and colorectal cancer.